A review of response in neoadjuvant therapy for exocrine pancreatic cancer. Issue 6 (8th April 2021)

• Record Type: Journal Article
• Authors: Vitello, Dominic J.; Bentrem, David J.
• Other Names: Bentrem David guestEditor.; Rocha Flavio G. guestEditor.
• Is Part Of: Journal of surgical oncology. Volume 123:Issue 6(2021)
• Page Start: 1449
• Page End: 1459
• Publication Date: 2021-04-08
• Subjects: exocrine pancreatic cancer -- neoadjuvant therapy -- pancreatic ductal adenocarcinoma -- response; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26369
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Despite overall advances in cancer therapy, patients with pancreatic ductal adenocarcinoma continue to have a poor prognosis. While adjuvant therapy is still considered standard, there is mounting evidence that neoadjuvant therapy confers similar benefits in patients with locally advanced disease. The primary measures of response are radiographic, biochemical, margin status, and pathologic. Given overall low response rates and the need for new treatment strategies, standard metrics remain important to the investigation of new systemic agents.